MiR-29b Alleviates High Glucose-induced Inflammation and Apoptosis in Podocytes by Down-regulating PRKAB2

Overview

Journal Endocr Metab Immune Disord Drug Targets

Publisher Bentham Science Publishers

Specialties Allergy & Immunology
Endocrinology
Infectious Diseases
Pharmacology

Date 2024 Jan 11

PMID 38204237

Authors

Hongxiu Du

Yakun Wang

Yingchun Zhu

Xiaoying Li

Tingying Zhu

Qianqian Wu

Fangfang Zha

Affiliations

Soon will be listed here.

Abstract

Background: Podocyte injury and inflammatory response are the core contributors to the pathogenesis of diabetic nephropathy. This study aims to identify novel regulatory miRNAs and elucidate their underlying mechanisms, which will help us understand the pathogenesis of diabetic nephropathy more comprehensively.

Materials And Methods: Different glucose concentrations were used to treat podocytes to mimic the pathology of diabetic nephropathy . Flow cytometry was used to determine cell apoptosis. Inflammatory cytokines released by podocytes were measured by using an enzymelinked immunosorbent assay (ELISA). Western Blot was used to detect the expression of PRKAB2 protein in podocytes.

Results: Genecard and g: profiler results revealed that miR-29b might be involved in regulating HG-induced cell injury. QRT-PCR indicated that HG-induced downregulation of miR-29b in podocytes. MiR-29b knockdown promoted cell apoptosis and inflammatory response in podocytes. MiR-29b overexpression repressed cell apoptosis and inflammatory response induced by high glucose treatment in podocytes. Luciferase reporter assay and Western Blot showed that miR-29b targeted PRKAB2 to negatively regulate PRKAB2 expression directly. Knockdown of PRKAB2 reversed the increased cell apoptosis and inflammation induced by miR-29b inhibitors.

Conclusion: MiR-29b plays a role in inhibiting inflammation and apoptosis in high glucose (HG) treated podocytes by negatively regulating PRKAB2 expression. This study provides new potential targets and ideas for the treatment of diabetic nephropathy.

References

Matoba K, Takeda Y, Nagai Y, Kawanami D, Utsunomiya K, Nishimura R . Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. Int J Mol Sci. 2019; 20(14). PMC: 6678414. DOI: 10.3390/ijms20143393. View

Iranzad R, Motavalli R, Ghassabi A, Pourakbari R, Etemadi J, Yousefi M . Roles of microRNAs in renal disorders related to primary podocyte dysfunction. Life Sci. 2021; 277:119463. DOI: 10.1016/j.lfs.2021.119463. View

Chen J, Xu Q, Zhang W, Zhen Y, Cheng F, Hua G . MiR-203-3p inhibits the oxidative stress, inflammatory responses and apoptosis of mice podocytes induced by high glucose through regulating Sema3A expression. Open Life Sci. 2021; 15(1):939-950. PMC: 7874591. DOI: 10.1515/biol-2020-0088. View

Li F, Dai B, Ni X . Long non-coding RNA cancer susceptibility candidate 2 (CASC2) alleviates the high glucose-induced injury of CIHP-1 cells via regulating miR-9-5p/PPARγ axis in diabetes nephropathy. Diabetol Metab Syndr. 2020; 12:68. PMC: 7409641. DOI: 10.1186/s13098-020-00574-8. View

Mohr A, Mott J . Overview of microRNA biology. Semin Liver Dis. 2015; 35(1):3-11. PMC: 4797991. DOI: 10.1055/s-0034-1397344. View

He M, Wang J, Yin Z, Zhao Y, Hou H, Fan J . MiR-320a induces diabetic nephropathy via inhibiting MafB. Aging (Albany NY). 2019; 11(10):3055-3079. PMC: 6555468. DOI: 10.18632/aging.101962. View

Qin X, Jiang M, Zhao Y, Gong J, Su H, Yuan F . Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis. Br J Pharmacol. 2019; 177(16):3646-3661. PMC: 7393204. DOI: 10.1111/bph.14935. View

Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P . Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. Eur J Pharmacol. 2016; 791:8-24. DOI: 10.1016/j.ejphar.2016.08.022. View

Ioannou K . Diabetic nephropathy: is it always there? Assumptions, weaknesses and pitfalls in the diagnosis. Hormones (Athens). 2018; 16(4):351-361. DOI: 10.14310/horm.2002.1755. View

10.

Ren F, Zhang M, Zhang C, Sang H . Psoriasis-Like Inflammation Induced Renal Dysfunction through the TLR/NF-B Signal Pathway. Biomed Res Int. 2020; 2020:3535264. PMC: 6996681. DOI: 10.1155/2020/3535264. View

11.

Su J, Ye D, Gao C, Huang Q, Gui D . Mechanism of progression of diabetic kidney disease mediated by podocyte mitochondrial injury. Mol Biol Rep. 2020; 47(10):8023-8035. DOI: 10.1007/s11033-020-05749-0. View

12.

Zhao S, Zhang T, Qiu Q, Xu C, Ma L, Liu J . MiRNA-337 leads to podocyte injury in mice with diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2019; 23(19):8485-8492. DOI: 10.26355/eurrev_201910_19161. View

13.

He J, Wu J, Dong S, Xu J, Wang J, Zhou X . Exosome-Encapsulated miR-31, miR-192, and miR-375 Serve as Clinical Biomarkers of Gastric Cancer. J Oncol. 2023; 2023:7335456. PMC: 9950326. DOI: 10.1155/2023/7335456. View

14.

Ismail A, El-Mahdy H, Eldeib M, Doghish A . miRNAs as cornerstones in diabetic microvascular complications. Mol Genet Metab. 2022; 138(1):106978. DOI: 10.1016/j.ymgme.2022.106978. View

15.

Zhang C, Zhong T, Li Y, Li X, Yuan X, Liu L . The hepatic AMPK-TET1-SIRT1 axis regulates glucose homeostasis. Elife. 2021; 10. PMC: 8592569. DOI: 10.7554/eLife.70672. View

16.

Podgorski P, Konieczny A, Lis L, Witkiewicz W, Hruby Z . Glomerular podocytes in diabetic renal disease. Adv Clin Exp Med. 2019; 28(12):1711-1715. DOI: 10.17219/acem/104534. View

17.

Prochazka M, Farook V, Ossowski V, Wolford J, Bogardus C . Variant screening of PRKAB2, a type 2 diabetes mellitus susceptibility candidate gene on 1q in Pima Indians. Mol Cell Probes. 2002; 16(6):421-7. DOI: 10.1006/mcpr.2002.0439. View

18.

Zhao Y, Li D, Zhou P, Zhao Y, Kuang J . microRNA-29b-3p attenuates diabetic nephropathy in mice by modifying EZH2. Hormones (Athens). 2023; 22(2):223-233. DOI: 10.1007/s42000-022-00426-2. View

19.

Schellinger I, Wagenhauser M, Chodisetti G, Mattern K, Dannert A, Petzold A . MicroRNA miR-29b regulates diabetic aortic remodeling and stiffening. Mol Ther Nucleic Acids. 2021; 24:188-199. PMC: 7957025. DOI: 10.1016/j.omtn.2021.02.021. View

20.

Zhou H, Ni W, Meng X, Tang L . MicroRNAs as Regulators of Immune and Inflammatory Responses: Potential Therapeutic Targets in Diabetic Nephropathy. Front Cell Dev Biol. 2021; 8:618536. PMC: 7868417. DOI: 10.3389/fcell.2020.618536. View